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oRIGINAL ARTICLE
Introduction: Tumor tissue is often not obtainable or suitable for 
molecular-based epidermal growth factor receptor (EGFR) muta-
tional analysis in advanced non–small-cell lung cancer (NSCLC). 
This retrospective and single-institution study was conducted to 
evaluate the role of effusion immunocytochemistry using two EGFR 
mutant-specific antibodies for the detection of relevant EGFR muta-
tions in NSCLC, along with the selection of candidates for first-line 
therapy with EGFR tyrosine kinase inhibitors (TKIs).
Methods: Immunocytochemistry using two antibodies binding spe-
cifically to the major forms of mutant EGFR, L858R, and E746-A750 
deletion (delE746-A750), was performed on cell blocks of malignant 
pleural effusion (MPE) from 78 patients with lung adenocarcinoma, 
who received first-line EGFR TKIs. The yield of EGFR-mutation 
detection and prediction of response rate and progression-free sur-
vival to TKI treatment by immunocytochemistry were compared 
with those by clinical characteristics and EGFR sequencing using 
cell-derived RNA from MPEs.
Results: of the 78 MPE samples, direct sequencing using cell-derived 
RNA identified L858R mutation in 42 cases, deletions in exon 19 in 
12 cases (delE746-A750 in eight cases), other types of mutations 
in three cases, and wild-type EGFR in 21 cases. Effusion immuno-
cytochemistry with these two mutant-specific antibodies exhibited 
a sensitivity of 71% and 88% and a specificity of 86% and 96% for 
identifying predefined L858R and delE746-A750 mutations, respec-
tively. Effusion immunocytochemistry provided a superior prediction 
of tumor response and progression-free survival to first-line EGFR 
TKIs than did clinical characteristics like sex and smoking status. 
Patients whose effusion immunocytochemistry showed a reaction 
to either of the two antibodies had a comparable TKI response rate 
(67% versus 72%) to those with EGFR mutations assessed by direct 
sequencing from cell-derived RNA.
Conclusions: Effusion immunocytochemistry could be introduced 
into clinical practice to identify more NSCLC patients likely to have 
benefit from first-line TKI treatment, especially for those without 
adequate tissue for molecular-based EGFR analysis.
Key Words: Non–small-cell lung cancer (NSCLC), Epidermal 
growth factor receptor (EGFR), Mutation, Malignant pleural effu-
sion, Immunocytochemistry.
(J Thorac Oncol. 2012;7: 993–1000)
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown favorable therapeutic effects 
in a subset of patients with advanced non–small-cell lung 
cancer (NSCLC).1,2 Somatic mutations in the tyrosine kinase 
domain of the EGFR gene are the major determinants of tumor 
response to EGFR TKIs.3–5 Ninety percent of clinically rel-
evant EGFR mutations associated with TKI efficacy are either 
an in-frame deletion in exon 19 or a single nucleotide substitu-
tion (L858R) in exon 21. The response rate to TKI treatment 
in patients with these sensitive mutations is approximately 
60% to 80%, in contrast to the 10% to 20% of response in 
wild-type cases.6 In addition, multiple randomized phase-III 
studies of genotype-selected patients with advanced NSCLC 
have demonstrated improved progression-free survival (PFS) 
and response rate with gefitinib compared with conventional 
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doublet chemotherapy.7–9 on the basis of these data, EGFR 
TKIs have emerged as a recommended first-line therapy in 
patients with EGFR-sensitizing mutations.
Since the discovery of EGFR mutations and their 
relationship to sensitivity of EGFR TKIs in NSCLC, muta-
tional analysis of EGFR has been the standard for selecting 
patients to be treated with targeted therapy.10 Current research 
is directed at optimizing implication of EGFR mutational 
testing so that it might be introduced into clinical practice. 
However, as the cases considered for EGFR-TKI therapy pres-
ent at advanced stages, diagnostic materials are often limited 
to small biopsies or cytological specimens, which may con-
tain insufficient tumor cells for molecular analysis. In fact, 
even in prospectively conducted clinical trials, less than 50% 
of patients with advanced NSCLC had adequate specimens 
available for EGFR mutational analysis.7 To this end, alter-
native approaches that can detect molecular markers from 
samples other than surgical tissues must be explored and uti-
lized to select more patients who are likely to respond to TKI 
treatment.
Malignant pleural effusion (MPE) is a common com-
plication of advanced NSCLC, and sampling of effusion 
fluid is minimally invasive and often easy. For many patients, 
MPEs may be the only obtainable specimen allowing for 
the collection of sufficient tumor cells for molecular analy-
sis. Nevertheless, because of the highly heterogeneous cel-
lularity and the difficulty in performing microdissection on 
cytological samples, analysis of EGFR mutations from MPE 
specimens is challenging.11 Even with high-sensitivity assays 
that are able to detect low-abundance mutations, EGFR muta-
tional analysis of cell-derived DNA may be insensitive for 
samples of MPE, which often contain substantial proportions 
of nontumor cells.12 Recently, we have documented that EGFR 
sequencing using cell-derived RNA instead of genomic DNA 
as the template greatly improved the sensitivity of analyzing 
EGFR status from specimens of MPE.12,13 Despite the promise 
of using RNA for EGFR-mutation detection from MPE sam-
ples, the inherently labile nature of RNA and the ubiquitous 
presence of RNase warrant the requisite of prudent sample 
processing and limit its popular application in clinical practice 
at present.14
Immunocytochemistry is a well-established technique 
and frequently applied as an adjuvant method for the evalu-
ation of MPEs.15 Recently, two rabbit monoclonal antibodies 
binding specifically to the two major forms of mutant EGFR, 
E746-A750 deletion (delE746-A750) in exon 19 and L858R 
point mutation in exon 21, have been developed for immunos-
taining.16 Compared to molecular-based EGFR tests, immu-
nocytochemistry is surpassingly simple, rapid, and low-cost, 
and can be performed in essentially all pathology laborato-
ries. Given the limitation of molecular-based EGFR analysis 
for samples of MPE, inclusion of these two mutant-specific 
antibodies in the panel of effusion immunocytochemistry in 
NSCLC may be a surrogate for selecting candidates for EGFR 
TKI treatment in patients with MPEs. In this study, we assessed 
the yield of immunocytochemistry using these two antibodies 
for the detection of relevant EGFR mutations from MPEs of 
lung adenocarcinoma, along with the utility for the selection 
of candidates for EGFR-TKI therapy in the first-line setting.
MATERIALS AND METHODS
Patients and Pleural Effusion Samples
Between June 2005 and october 2009, we collected 
samples of cytology-proven MPEs for the retrospective anal-
ysis of EGFR mutations from patients with advanced lung 
adenocarcinoma who received gefitinib or erlotinib as the first-
line antitumor treatment.12 of these effusion samples, those 
(n = 78) also processed separately for cell-block preparations 
were included in this study. The clinical characteristics of the 
78 patients are summarized in Table 1. These subjects repre-
sented a part of the cohort in our previously reported study.12 
This study was approved by the Institutional Review Board 
of National Taiwan University Hospital (approval number: 
993703374), and all patients had signed an informed consent 
form for the use of samples in molecular analyses. Patients 
who had smoked fewer than 100 cigarettes in their lifetime 
were categorized as never smokers.
TABLE 1. Clinical Characteristics and EGFR-Mutation Status 
of the Patients
Characteristic Value
Total no. 78
Sex—no. (%)
 Male 32 (41)
 Female 46 (59)
Age yrs—no. (%)
 65 27 (35)
 65 51 (65)
Smoking status—no. (%)
 Never smoker 55 (71)
 Current or former smoker 23 (29)
ECoG performance status score—no. (%)
 0–1 54 (69)
 2 24 (31)
EGFR-TKI treatment—no. (%)
 Gefitinib 66 (85)
 Erlotinib 12 (15)
Genotyping of tumor cellsa—no. (%)
 L858R mutation 42 (54)
 Exon 19 deletions 12 (15)
 del E746-A750 8
 del E746-T751 insVP 1
 del L747-S752 2
 del L747-P753 insS 1
 other mutations 3 (4)
 Wild-type 21 (27)
Best response to EGFR TKIs—no. (%)
 Partial response 43 (55)
 Stable disease 5 (6)
 Progressive disease 30 (38)
aBy PCR-based sequencing using cell-derived RNA as the template from samples of 
malignant pleural effusions.
EGFR, epidermal growth factor receptor; ECoG, Eastern Cooperative oncology 
Group; TKI, tyrosine kinase inhibitor; delE746-A750, E746-A750 deletion.
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Mutational Analysis of EGFR by Direct 
Sequencing From Cell-Derived RNA
Mutational analysis of the EGFR gene using cell-
derived RNA as the template from MPEs was performed as 
previously reported.12,13 In summary, total RNA was extracted 
from cell pellets after centrifugation of MPEs. Exons 18 to 21 
of the EGFR gene were amplified in a reverse transcription-
polymerase chain reaction (RT-PCR) using the Qiagen one-
Step RT-PCR Kit (Qiagen, Valencia, CA), with the primers 
and RT-PCR conditions as previously described.12 The cDNA 
amplicons were purified and sequenced on an automatic ABI 
PRISM 3700 genetic analyzer (Applied Biosystems, Foster 
City, CA). Both the forward and reverse sequences obtained 
were analyzed. EGFR mutations detected in the initial round 
of sequencing were confirmed by a subsequent independent 
RT-PCR and sequencing reactions.
Immunocytochemical Analysis Using EGFR 
Mutant-Specific Antibodies
For effusion immunocytochemistry, serial 4-μm-thick 
sections were cut from each paraffin-embedded cell block. 
Deparaffinized sections were pretreated with a microwave 
antigen retrieval system (Biogenex, San Ramon, CA). The 
sections were then incubated with 3% hydrogen peroxidase 
for 10 minutes and Power Block (Biogenex) for 30 minutes 
to block intrinsic peroxidase activity and nonspecific bind-
ing. After washing, the slides were incubated with diluted 
primary antibodies (1:150) at 48C overnight. The primary 
antibodies used were a rabbit monoclonal antibody against 
human EGFR with the delE746-A750 mutation (clone 6B6; 
Cell Signaling Technology, Danvers, MA) and against human 
EGFR with the L858R mutation (clone 43B2; Cell Signaling 
Technology), and a mouse monoclonal antibody against 
human EGFR (clone 31G7; Invitrogen, Carlsbad, CA) for 
controlling the immunostaining. The immunoreactions were 
detected using a Super Sensitive Non-Biotin Polymer HRP 
Detection System (Biogenex) with diaminobenzidine as a 
chromogen and counterstaining with hematoxylin.
Two observers (y.-L. Chang and C.-T. Wu) blind to the 
data of EGFR sequencing evaluated the staining results inde-
pendently, and differences in interpretation were resolved by 
consensus. The intensity score was established as follows: 0 if 
tumor cells had a complete absence of staining or faint stain-
ing intensity of less than 10%; 1+ if more than 10% of the 
tumor cells had faint staining; 2+ if the tumor cells had mod-
erate staining; and 3+ if the tumor cells had strong staining. A 
score of 1+, 2+, and 3+ expressions was considered positive 
for immunoreactivity, as previously described.16
Evaluation of the Response to  
First-Line EGFR TKIs
Treatment response to first-line EGFR TKIs was defined 
according to the criteria of the Response Evaluation Criteria 
in Solid Tumors group (version 1.1).17 Chest radiography 
was routinely carried out every 2 to 3 weeks after the start 
of EGFR-TKI therapy with gefitinib or erlotinib, whereas 
computed tomography of the chest and other disease sites was 
performed every 8 to 12 weeks and as needed to evaluate the 
response to treatment. PFS was calculated from the first day of 
TKI administration until the earliest sign of disease progres-
sion or death from any cause.
Statistical Analyses
The sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV), and diagnostic accu-
racy were calculated using standard statistical methods. All 
qualitative variables were analyzed with χ2 tests, except when a 
small size (<5) necessitated the use of Fisher’s exact test. PFSs 
after first-line TKIs were analyzed by the Kaplan-Meier method, 
and were compared between groups by the Wilcoxon test. Two-
sided p values of less than 0.05 were considered statistically 
significant. All analyses were performed using SPSS software 
(version 12.0 for Windows; SPSS Inc., Chicago, IL).
RESULTS
Detection of EGFR Mutations by  
Direct Sequencing Using Cell-Derived  
RNA as the Template
of the total 78 samples of MPEs related to lung ade-
nocarcinoma, direct sequencing using cell-derived RNA as 
the template identified EGFR mutations in 57 cases (73%), 
as shown in Table 1. These mutations included the L858R 
mutation in 42 cases (54%), deletions in exon 19 in 12 cases 
(15%), and other types of mutations in three cases (4%). 
Among the 12 cases with deletions in exon 19, eight cases had 
a 15-base-pair deletion in the range of E746-A750, whereas 
the other types of deletion in exon 19 included delE746-T751 
insVP, delL747-S752 and delL747-P753 insS in four cases. 
Mutations other than L858R mutation or deletions in exon 19 
included L861Q, K806E, and complex mutations of G719A 
and S768I.
Sixty-three percent of men (20 of 32) and 80% of women 
(37 of 46, p = 0.079 for men versus women) were found to 
have tumors harboring EGFR mutations, with mutations in 
men representing 35% of all those detected. EGFR mutations 
were found in 65% of tumors from current or former smokers 
(15 of 23) and 76% of tumors from never smokers (42 of 55, 
p = 0.312 for current or former smokers versus never smok-
ers). EGFR mutations in current or former smokers repre-
sented 26% of all mutations detected.
Immunocytochemistry-Based Identification of 
EGFR Mutations
The staining intensity of immunocytochemistry using 
the two mutant-specific antibodies on the examined samples, 
and their relationship with the results of EGFR sequencing 
from RNA are shown in Table 2. The representative pictures 
are shown in Figure 1 in each case of cancers carrying wild-
type EGFR, the L858R mutation, and the delE746-A750 
mutation, respectively. of the 78 effusion cell blocks, 35 
cases (45%) were scored positive for EGFR L858R mutant-
specific antibody, and 10 cases (13%) were scored positive for 
the delE746-A750 antibody using the scoring criteria previ-
ously described. of the four samples that were identified by 
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sequencing as carrying exon 19 deletions other than delE746-
A750, all were negatively stained with the delE746-A750 
antibody (Table 2).
EGFR sequencing from RNA was used as the stan-
dard procedure, and the capacities for detection of EGFR 
mutations by effusion immunocytochemistry were assessed 
(Table 3). Immunocytochemical analysis with the L858R 
mutant-specific antibody showed a sensitivity of 71% (30 of 
42), a specificity of 86% (31 of 36), a diagnostic accuracy of 
78% (61 of 78), a PPV of 86% (30 of 35), and a NPV of 72% 
(31 of 43). The delE746-A750 antibody exhibited a higher 
diagnostic yield. The sensitivity, specificity, diagnostic accu-
racy, PPV, and NPV to detect delE746-A750 in exon 19 were 
88% (7 of 8), 96% (67 of 70), 95% (74 of 78), 70% (7 of 10), 
and 99% (67 of 68), respectively. However, if exon 19 dele-
tions other than delE746-A750 were also considered, the sen-
sitivity, specificity, diagnostic accuracy, PPV, and NPV were 
58% (7 of 12), 95% (63 of 66), 90% (70 of 78), 70% (7 of 10), 
and 93% (63 of 68), respectively.
Focusing on the clinical need to detect any common 
EGFR mutations, we calculated the combined yield of immu-
nostaining with the two mutant-specific antibodies, and found 
TABLE 2. Correlation Between the Results of Effusion Immunocytochemistry and EGFR Sequencing 
From Cell-Derived RNA
EGFR sequencing 0 1+ 2+ 3+ Total
Immunocytochemistry with L858R antibody
L858R mutation , n (%) 12 (29) 1 (2) 9 (21) 20 (48) 42
L858R mutation , n (%) 31 (86) 0 (0) 4 (11) 1 (3) 36
Total, n 43 1 13 21 78
Immunocytochemistry with delE746-A750 antibody
Exon 19 deletion , n (%) 5 (42) 0 (0) 0 (0) 7 (58) 12
 delE746-A750 1 0 0 7 8
 delE746-T751 insVP 1 0 0 0 1
 delL747-S752 2 0 0 0 2
 delL747-P753 insS 1 0 0 0 1
Exon 19 deletion −, n (%) 63 (95) 1 (2) 1 (2) 1 (2) 66
Total, n 68 1 1 8 78
EGFR, epidermal growth factor receptor; delE746-A750, E746-A750 deletion.
FIGURE 1. Representative immunocy-
tochemical staining in cell-block samples of 
malignant pleural effusion related to lung 
adenocarcinoma. (A) A sample without  
EGFR-mutant tumor cells was negatively 
stained with the two EGFR mutant-specific 
antibodies. (B) A sample with tumor cells  
harboring L858R mutation was positively 
stained with the L858R-specific antibody.  
(C) A sample with tumor cells harboring 
E746-A750 deletion was positively stained 
with the delE746-A750-specific antibody. 
Note that the mutation-specific antibodies 
had immunoreactivity mainly for the cell 
membrane of the tumor cells. delE746-A750, 
E746-A750 deletion. EGFR, epidermal growth 
factor receptor.
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74% sensitivity (37 of 50) and 82% specificity (23 of 28) for 
detecting the predefined EGFR mutations (L858R mutation 
and delE746-A750), and 69% sensitivity (37 of 54) and 79% 
specificity (19 of 24) to detect any L858R mutations and exon 
19 deletions (Table 3).
Prediction of Treatment Outcomes by Clinical 
Characteristics, Effusion Immunocytochemistry 
and EGFR Sequencing from Cell-Derived RNA
We evaluated the contribution of clinical characteristics, 
and EGFR status assessed by effusion immunocytochemistry 
or EGFR sequencing from RNA, for the prediction of response 
rate and PFS to first-line EGFR TKIs among these patients 
(Table 4 and Fig. 2). The response rates and PFSs were not 
statistically different between sex and smoking status. In con-
trast, patients with positive results of effusion immunochemis-
try with either of the two antibodies had a significantly better 
response rate (67% versus 42%, p = 0.027) and PFS (median, 
6.1 months versus 2.0 months, p = 0.021) than those with a 
negative staining. EGFR mutational status assessed by direct 
sequencing using RNA as the template represented the most 
robust predictor both for the response rate (72% for those with 
L858R mutations or deletions in exon 19 versus 17% for those 
without these mutations, p  0.001) and PFS (median, 7.2 
months versus 1.2 months, p  0.001).
DISCUSSION
In this study, we demonstrated the feasibility of immu-
nophenotypic identification of relevant EGFR mutations by 
using the two mutant-specific antibodies from cell-block prep-
arations of MPEs. Compared to clinical characteristics includ-
ing sex and smoking status, effusion immunocytochemistry 
with these antibodies provided a superior prediction of tumor 
response and PFS to first-line EGFR TKIs. Moreover, patients 
whose effusion immunocytochemistry was reactive to either 
of the two antibodies had a comparable TKI response rate 
(67% versus 72%) to those with EGFR mutations assessed 
by the molecular-based method; this justified the selection of 
these patients by effusion immunocytochemistry to receive 
EGFR TKIs in the first-line setting.
Although EGFR mutations in NSCLC occur prefer-
entially in women, never smokers, and those with adenocar-
cinoma histology, an arbitrary selection of patients for TKI 
treatment on the basis of their clinical characteristics cannot 
replace EGFR testing.18,19 In a multi-institutional study con-
ducted in Spain, EGFR mutations were present in 8%, 10%, 
and 6% of men, former and current smokers with NSCLC, 
respectively.20 Pham et al.21 found that EGFR mutations were 
present in 51% of patients with lung adenocarcinoma, who 
were never smokers, with a similar incidence of mutations 
in men and women. In our series of patients with MPEs of 
lung adenocarcinoma in Taiwan, tumors from 63% of men 
and 65% of current or former smokers harbored EGFR muta-
tions, as assessed by EGFR sequencing using RNA from MPE 
samples. We showed that the response rate and PFS of men 
TABLE 3. Detection Capabilities of the Effusion 
Immunocytochemistry Using EGFR Mutant-Specific 
Antibodies
Sensitivity 
(%)
Specificity 
(%)
Accuracy 
(%)
PPV 
(%)
NPV 
(%)
L858R 71 86 78 86 72
E746-A750  
deletion
88 96 95 70 99
All exon 19 
deletions
58 95 90 70 93
L858R + E746-
A750 deletion
74 82 77 88 64
L858R + all exon  
19 deletions
69 79 72 88 53
EGFR, epidermal growth factor receptor; PPV, positive predictive value; NPV, 
negative predictive value.
TABLE 4. Prediction of Clinical Response and Progression-Free Survival to First-Line EGFR Tyrosine Kinase Inhibitors
Variable No. of Subjects No. of Respondersa p-Value PFS (months) p-Value
Sex 0.448 0.401
 Female 46 27 (59%) 6.0
 Male 32 16 (50%) 4.2
Smoking status 0.402 0.502
 Never smoker 55 32 (58%) 6.0
 Current or former smoker 23 11 (48%) 4.2
Immunocytochemistry with mutant-specific antibodies 0.027 0.021
 Positive stainingb 42 28 (67%) 6.1
 Negative staining 36 15 (42%) 2.0
EGFR sequencing from cell-derived RNA <0.001 <0.001
 With L858R or exon 19 deletions 54 39 (72%) 7.2
 Without L858R or exon 19 deletions 24 4 (17%) 1.2
aIncluding patients with complete or partial responses.
bEffusion immunocytochemistry reactive to either of the two EGFR mutant-specific antibodies.
EGFR, epidermal growth factor receptor; PFS, progression-free survival.
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and smokers were not significantly different from those seen 
in women and never smokers, further revealing that it is the 
EGFR mutations and not the clinical factors that underlie 
the treatment outcome. Thus, subset selection based solely 
on favorable clinical characteristics would miss a substantial 
number of patients likely to benefit from targeted treatment, 
especially in Asian areas where EGFR-mutant NSCLC is 
more prevalent. our results support the growing consensus for 
universal analysis of EGFR status at diagnosis for those with 
lung adenocarcinoma, regardless of clinical characteristics, 
as illustrated in the National Comprehensive Cancer Network 
guidelines, European Society for Medical oncology consen-
sus, and American Society of Clinical oncology guideline on 
EGFR testing.10,22,23
EGFR mutational analysis in NSCLC requires the avail-
ability of sufficient tumor cells. Moreover, a minimum of 50% of 
tumor cells (25% of mutant alleles) on the specimen is required 
for reliable mutational analysis using direct DNA sequencing.24 
In many circumstances, however, tumor tissue is not obtain-
able or suitable for molecular-based EGFR tests. For NSCLC 
patients with MPEs, cytological cell-block preparation from 
MPEs may represent an alternative for the collection of tumor 
cells for molecular analysis.25 More than 150,000 patients are 
diagnosed with MPEs annually in the United States, with lung 
cancer as the most common (40%) etiology.26 In fact, up to 
50% of patients with advanced lung cancer may acquire MPEs 
during the course of their diseases.27 Despite their high preva-
lence in advanced NSCLC, MPEs are currently underutilized 
FIGURE 2. Kaplan-Meier analysis of progression-free survival after the start of treatment with first-line EGFR tyrosine kinase 
inhibitors. Patients were classified according to sex (A), smoking status (B), results of effusion immunocytochemistry with the 
two EGFR mutant-specific antibodies (C), and EGFR mutational status assessed by direct sequencing using cell-derived RNA from 
malignant pleural effusions (D). EGFR, epidermal growth factor receptor.
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for EGFR mutational analysis. The intrinsic nature of highly 
heterogeneous cellularity and difficulty in performing micro-
dissection on the sample has strongly limited their use for 
DNA-based EGFR tests.12 In contrast to the molecular-based 
approach, the interpretation of immunocytochemistry results 
depends on the intensity of staining of individual cancer cells 
rather than on the results from the whole lysates.16 As a result, 
mutations in effusion samples with a low percentage of tumor 
cells can be theoretically detected by immunocytochemistry 
using the two mutant-specific antibodies.
Evaluating the performance of effusion immunocy-
tochemistry with the two mutant-specific antibodies is required 
before application of this technique in routine practice. Recently, 
Kawahara et al.28 reported high sensitivity (100%) and specific-
ity (91%) of immunocytochemistry using the two antibodies 
for cytospin samples of malignant effusion and cerebrospinal 
fluid. However, the number of cases in this study was small 
(n = 24) and the association between the immunostaining and 
treatment efficacy of EGFR TKIs was not revealed. To the best 
of our knowledge, ours is the first large scale study to provide 
the diagnostic yield of effusion immunocytochemistry for the 
detection of common EGFR mutations, along with associat-
ing the assay with prediction of treatment outcomes in NSCLC 
patients receiving first-line EGFR TKIs.
Compared with the results for histological samples, 
our study showed that the specificity of immunostaining for 
effusion cell blocks using the two antibodies are modestly 
lower (86% and 96% for the detection of L858R mutation 
and E746-A750 deletion, respectively). Studies have consis-
tently reported very high specificity (96%–100%) of immu-
nohistochemistry assay for the detection of EGFR mutations 
in histological tissues.16,29–35 Although paraffin-embedded 
cell blocks are considered suitable for effusion immunocy-
tochemistry, there are several differences between cell blocks 
and surgical specimens that probably influence the results of 
immunostaining.15 First, cell blocks from effusions tend to 
have smaller cell clusters rather than tissue fragments as in 
histological samples. Second, the highly proteinaceous effu-
sion itself, in which cells are floating, may contribute to unex-
pected immunoreactivity. Finally, membrane staining of tumor 
cells may be difficult to distinguish from nonspecific staining 
of adjacent nontumor cells.
our data revealed that effusion immunocytochemistry 
with the two mutant-specific antibodies, though less robust 
than RNA-based EGFR sequencing, had a more useful value 
for predicting TKI response than clinical characteristics did. 
Thus, for those with NSCLC and MPEs but without adequate 
histological tissues, the readily available effusion immuno-
cytochemistry could be regarded as a suitable alternative for 
EGFR mutational analysis. Patients whose effusion immu-
nocytochemistry showed a reaction to either of the two anti-
bodies could be subject to EGFR-TKI treatment, given the 
similar response rate (67% versus 72%) to those selected by 
the sensitive molecular-based method from MPE samples. 
Nevertheless, the sensitivity of effusion immunocytochem-
istry using the two antibodies was not optimal, thus leading 
to a high response rate (42%) in our patients with negative 
staining. Moreover, as shown in this study, this assay was 
unable to identify deletions other than E746-A750 in exon 
19. other less common sensitive mutations, such as G719A/S 
and L861Q, are not the targets of the two antibodies used for 
immunocytochemistry. Therefore, a percentage of patients, 
despite having EGFR-mutant tumors, will still not be identi-
fied by this technique. This limitation of immunocytochemi-
cal analysis for the detection of EGFR mutations needs to be 
acknowledged in clinical use.
At present, there is no standard scoring scheme for the 
assessment of EGFR expression by immunohistochemistry 
or immunocytochemistry.36 However, most of the published 
studies have adapted an intensity scoring method for immuno-
histochemical identification of EGFR mutations using mutant-
specific antibodies, specifying a detectable staining in at least 
10% of the tumor cells as a criterion for test positivity.16,29,30,34,35 
on the basis of these data, patients in this study were consid-
ered to be positive for effusion immunocytochemistry when 
more than 10% of the tumor cells were stained with the two 
EGFR mutant-specific antibodies.
Limitations in this analysis are that this is a retrospec-
tive study and a single-institution series, and that there were 
fewer patients harboring deletions in exon 19 in our cohort 
compared to the reported distribution of EGFR mutations in 
NSCLC (with deletions in exon 19 generally accounting for 
40%–50% of all EGFR mutations).6 The minor proportion of 
deletions in exon 19 in this study probably resulted from the 
relatively limited number of cases and the related effect of 
patient selection, and might influence the diagnostic indices 
of effusion immunocytochemistry. Moreover, the timing for 
imaging with computed tomography to evaluate EGFR-TKI 
response was variable (every 8–12 weeks after the start of 
therapy and as needed), and therefore, this might represent a 
bias for the assessment of PFS.
In conclusion, effusion immunocytochemistry 
using EGFR mutant-specific antibodies offers an alternative 
and practical approach to identify patients potentially respon-
sive to EGFR TKIs, especially for those without adequate 
tissue for molecular-based EGFR analysis. Incorporation of 
these two antibodies into the immunostaining panel expands 
the role of immunocytochemistry from being a method of 
effusion diagnostics to a therapeutic decision in advanced 
NSCLC.
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